Association between pNF-H and ALSFRS-R rate of change per month
| 0–4 months | 0–12 months | ||||||
|---|---|---|---|---|---|---|---|
| Cohort | pNF-H sample | ALSFRS-R slope† | r | p Value | ALSFRS-R slope† | r | p Value |
| Mayo 12 month (n=20) | CSF | −1.0 (−1.6, −0.2) | −0.59 | 0.006 | −0.9 (−1.4, −0.6) | −0.54 | 0.015 |
| Serum | −0.46 | 0.042 | −0.31 | 0.19 | |||
| Plasma | −0.38 | 0.095 | −0.25 | 0.29 | |||
| Mayo 4 month (n=19)‡ | Plasma | −0.8 (−2.1, −0.5) | −0.36 | 0.13 | NA | ||
| Both Mayo cohorts (n=38)§ | Plasma | −0.9 (−1.7, −0.4) | −0.35 | 0.030 | NA | ||
Associations between pNF-H and ALSFRS-R rate of change are estimated by Spearman's rank correlation r and corresponding p value.
†ALSFRS-R slope expressed in points per month and summarised by median (IQR).
‡One patient had only one follow-up assessment of ALSFRS-R and was excluded from this analysis; with the patient included in the analysis, Spearman's r was −0.19 (p=0.43).
§One patient was enrolled in both Mayo cohorts; only data from the Mayo 4 month cohort was included in the analysis combining both cohorts.
ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale; NA, data not collected; pNF-H, phosphorylated neurofilament heavy subunit.